Nephrotic Syndrome – Epidemiology Forecast– 2034

Nephrotic Syndrome – Epidemiology Forecast– 2034

Key Highlights

DelveInsight’s analyst projects that among the total diagnosed prevalent cases of Nephrotic Syndrome in 7MM was around 786 thousand and approximately 34% of cases were from the US. As per our estimations, in 2022, the EU4 and the UK accounted for nearly 367 thousand diagnosed prevalent cases of Nephrotic Syndrome.

Among EU4 and the UK, approximately 238 thousand and 128 thousand cases were identified as primary and secondary glomerulonephropathies, respectively in type-specific diagnosed prevalent cases of Nephrotic Syndrome in 2022. It was observed that there were more cases of primary glomerulonephropathies than secondary glomerulonephropathies, due to diagnostic challenges in recognizing secondary forms.

The total diagnosed prevalent cases of Nephrotic Syndrome in Japan, in 2022 were approximately 151 thousand cases. These cases are expected to change during the study period.

DelveInsight’s “Nephrotic Syndrome – Epidemiology – 2034” report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Disease Understanding and Diagnostic Algorithm

Nephrotic Syndrome Overview

Nephrotic syndrome is a clinical syndrome defined by massive proteinuria responsible for hypoalbuminemia, with resulting hyperlipidemia, edema, and various complications. Nephrotic syndrome may stem from diverse underlying factors, encompassing conditions like minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, lupus nephritis, diabetic nephropathy, infections, genetic disorders, specific medications, and more. Prolonged nephrotic syndrome can result in complications such as infections, malnutrition, and an elevated risk of cardiovascular disease. Consequently, accurately pinpointing the precise cause is imperative for effective treatment and comprehensive management.

From a pathological standpoint, nephrotic syndrome entails changes in the structure and function of the glomeruli, which are the small filtration units in the kidneys tasked with eliminating waste and surplus fluids from the blood. The key characteristics of nephrotic syndrome involve heightened permeability of the glomerular filtration barrier, leading to the excretion of proteins, notably albumin, in the urine.

Nephrotic Syndrome Diagnosis

The diagnostic process for nephrotic syndrome encompasses a clinical assessment, blood examinations to evaluate serum albumin and lipid concentrations, urine analyses to detect proteinuria and imaging modalities such as ultrasound. Additionally, a kidney biopsy may be undertaken to pinpoint the root cause, aiding in informed treatment choices. This comprehensive approach ensures a thorough understanding of the condition's nuances, facilitating precise diagnosis and tailored interventions.

Further details related to diagnosis are provided in the report…

Nephrotic Syndrome Epidemiology

As the market is derived using the patient-based model, the Nephrotic Syndrome epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Nephrotic Syndrome and Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per DelveInsight’s estimations, the total diagnosed prevalent cases of Nephrotic Syndrome in the 7MM were approximately 786 thousand in 2022, which are projected to increase during the forecast period due to rising population with obesity and diabetes.

Delveinsight's analysis in 2022 revealed that the total diagnosed prevalent cases of nephrotic syndrome in the US stood at approximately 267 thousand. Among these cases, primary glomerulonephropathies contributed to a substantial portion, accounting for around 214 thousand cases, while secondary glomerulonephropathies contributed to approximately 53 thousand cases. These numbers are anticipated to escalate during the forecast period from 2023 to 2034, indicating a growing health concern that necessitates attention and resources.

In EU4 and the UK, the diagnosed prevalent cases of nephrotic syndrome were estimated to be around 367 thousand in 2022. Among these regions, Germany emerged with the highest number of diagnosed prevalent cases, totaling approximately 98 thousand. Following closely behind, the UK reported around 87 thousand cases, indicating a considerable burden within these healthcare systems. Conversely, Spain reported the least number of cases among the EU4 and the UK, with approximately 48 thousand cases.

In Japan, a notable breakdown of nephrotic syndrome cases in 2022 revealed approximately 120 thousand cases attributed to primary glomerulonephropathies and around 30 thousand cases attributed to secondary glomerulonephropathies.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Nephrotic Syndrome evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from Medical School, Hannover, Hôpital Robert-Debré, APHP, Paris, Istituto G. Gaslini, Genoa, Hospital Universitario Fundación Jiménez Díaz, UCL Department of Renal Medicine, National Health Service, England, Fukushima Medical University, Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Japan, and others, and others.

Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Nephrotic Syndrome, explaining its causes, signs and symptoms, and pathogenesis.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Nephrotic Syndrome Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Diagnosed Prevalent Cases of Nephrotic Syndrome

Type-specific Diagnosed Prevalent Cases of Nephrotic Syndrome

Nephrotic Syndrome Report Key Strengths

12 years Forecast

The 7MM Coverage

Nephrotic Syndrome Epidemiology Segmentation

Key Questions

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of Nephrotic Syndrome? What will be the growth opportunities across the 7MM concerning the patient population of Nephrotic Syndrome?

What is the historical and forecasted Nephrotic Syndrome patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Why do only limited patients appear for diagnosis?

Which country is more prevalent for Nephrotic Syndrome and why?

What factors are affecting the diagnosis of the indication?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Nephrotic Syndrome prevalence cases in varying geographies over the coming years.

A detailed overview of Severity, Gender, and Age-specific prevalence of Nephrotic Syndrome.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Nephrotic Syndrome Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Nephrotic Syndrome cases in 2022?

The highest cases of Nephrotic Syndrome was found in the Germany among EU4 and the UK in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Nephrotic Syndrome cases in 2022?

The highest cases of Nephrotic Syndrome were found in the US among the 7MM in 2022.